Syngene International Ltd
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]
- Market Cap ₹ 34,248 Cr.
- Current Price ₹ 851
- High / Low ₹ 946 / 608
- Stock P/E 78.0
- Book Value ₹ 107
- Dividend Yield 0.15 %
- ROCE 13.4 %
- ROE 12.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 7.93 times its book value
- The company has delivered a poor sales growth of 11.9% over past five years.
- Company has a low return on equity of 13.0% over last 3 years.
- Dividend payout has been low at 10.5% of profits over last 3 years
- Promoter holding has decreased over last 3 years: -15.7%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Part of Nifty 500 Multicap 50:25:25 Nifty 500 BSE 400 MidSmallCap Index Nifty Total Market Nifty MidSmall Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
550 | 700 | 860 | 1,107 | 1,201 | 1,423 | 1,826 | 2,012 | 2,179 | 2,601 | 3,194 | 3,203 | 3,204 | |
382 | 485 | 579 | 727 | 816 | 950 | 1,290 | 1,395 | 1,504 | 1,861 | 2,252 | 2,322 | 2,349 | |
Operating Profit | 168 | 214 | 281 | 380 | 385 | 473 | 536 | 617 | 676 | 741 | 942 | 881 | 856 |
OPM % | 31% | 31% | 33% | 34% | 32% | 33% | 29% | 31% | 31% | 28% | 29% | 28% | 27% |
4 | 8 | 12 | 6 | 94 | 53 | 75 | 153 | 94 | 75 | 63 | 74 | 106 | |
Interest | 6 | 0 | 8 | 8 | 18 | 23 | 32 | 35 | 28 | 24 | 45 | 30 | 29 |
Depreciation | 60 | 66 | 81 | 97 | 114 | 131 | 164 | 219 | 274 | 310 | 359 | 369 | 375 |
Profit before tax | 106 | 157 | 204 | 281 | 346 | 372 | 414 | 516 | 467 | 482 | 601 | 557 | 558 |
Tax % | 4% | 14% | 14% | 14% | 17% | 18% | 20% | 20% | 14% | 18% | 21% | 16% | |
102 | 135 | 175 | 241 | 287 | 305 | 331 | 412 | 404 | 394 | 473 | 466 | 460 | |
EPS in Rs | 9.43 | 12.45 | 4.38 | 6.02 | 7.18 | 7.63 | 8.27 | 10.29 | 10.09 | 9.83 | 11.78 | 11.60 | 11.44 |
Dividend Payout % | 0% | 0% | 239% | 8% | 7% | 7% | 3% | 0% | 0% | 10% | 11% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 12% |
3 Years: | 14% |
TTM: | -4% |
Compounded Profit Growth | |
---|---|
10 Years: | 13% |
5 Years: | 7% |
3 Years: | 7% |
TTM: | -9% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 12% |
1 Year: | 18% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 14% |
3 Years: | 13% |
Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 26 | 26 | 199 | 200 | 200 | 200 | 200 | 400 | 400 | 401 | 401 | 402 | 402 |
Reserves | 492 | 633 | 646 | 825 | 1,213 | 1,520 | 1,767 | 1,774 | 2,418 | 2,891 | 3,218 | 3,790 | 3,916 |
4 | 155 | 155 | 891 | 806 | 787 | 813 | 773 | 893 | 1,022 | 639 | 332 | 364 | |
201 | 377 | 422 | 440 | 555 | 681 | 922 | 1,215 | 1,166 | 1,247 | 1,590 | 1,310 | 1,068 | |
Total Liabilities | 724 | 1,191 | 1,422 | 2,356 | 2,775 | 3,188 | 3,702 | 4,162 | 4,878 | 5,561 | 5,848 | 5,834 | 5,750 |
381 | 394 | 503 | 580 | 810 | 1,030 | 1,377 | 2,020 | 2,201 | 2,393 | 2,260 | 2,318 | 2,318 | |
CWIP | 9 | 45 | 105 | 237 | 175 | 155 | 274 | 234 | 237 | 346 | 126 | 760 | 809 |
Investments | 69 | 352 | 146 | 277 | 540 | 158 | 716 | 777 | 702 | 1,034 | 941 | 928 | 932 |
265 | 399 | 667 | 1,262 | 1,249 | 1,845 | 1,336 | 1,132 | 1,737 | 1,787 | 2,521 | 1,829 | 1,692 | |
Total Assets | 724 | 1,191 | 1,422 | 2,356 | 2,775 | 3,188 | 3,702 | 4,162 | 4,878 | 5,561 | 5,848 | 5,834 | 5,750 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
104 | 300 | 18 | 308 | 398 | 446 | 630 | 677 | 698 | 582 | 838 | 913 | |
-150 | -375 | 16 | -753 | -470 | -350 | -646 | -424 | -629 | -611 | -685 | -383 | |
21 | 155 | -10 | 716 | -81 | -79 | -72 | -226 | 58 | -31 | -340 | -536 | |
Net Cash Flow | -26 | 80 | 24 | 272 | -153 | 17 | -88 | 28 | 127 | -60 | -187 | -6 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 51 | 49 | 76 | 61 | 60 | 68 | 68 | 72 | 79 | 71 | 55 | 49 |
Inventory Days | 45 | 28 | 59 | 44 | 37 | 82 | 30 | 18 | 41 | 87 | 141 | 95 |
Days Payable | 208 | 146 | 106 | 87 | 116 | 194 | 154 | 157 | 166 | 115 | 110 | 104 |
Cash Conversion Cycle | -112 | -68 | 29 | 18 | -19 | -44 | -56 | -67 | -45 | 44 | 86 | 41 |
Working Capital Days | 5 | -61 | -6 | -10 | -14 | -28 | -65 | -115 | -19 | -4 | 32 | -22 |
ROCE % | 25% | 23% | 23% | 20% | 18% | 16% | 17% | 17% | 14% | 13% | 15% | 13% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
9h - Schedule of meeting with analyst/institutional investor.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Nov - Details of the meeting to be held with the Analyst/Institutional Investor.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
6 Nov - Details of the meeting to be held with the Analyst/Institutional Investor.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
6 Nov - Details of the meeting to be held with the Analyst/ Institutional Investor.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
29 Oct - Intimation of Q2 FY2025 Earnings Call transcript.
Annual reports
Concalls
-
Oct 2024Transcript PPT
-
Jul 2024Transcript PPT REC
-
Jul 2024TranscriptNotesPPT
-
Apr 2024TranscriptPPT
-
Jan 2024TranscriptNotesPPT
-
Jan 2024Transcript PPT
-
Oct 2023Transcript PPT
-
Jul 2023Transcript PPT
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Oct 2022TranscriptNotesPPT
-
Jul 2022TranscriptNotesPPT
-
Apr 2022TranscriptNotesPPT
-
Jan 2022Transcript PPT
-
Oct 2021Transcript PPT
-
Jul 2021Transcript PPT
-
Apr 2021TranscriptNotesPPT
-
Mar 2021TranscriptPPT
-
Jan 2021TranscriptNotesPPT
-
Oct 2020Transcript PPT
-
Jul 2020Transcript PPT
-
May 2020Transcript PPT
-
Feb 2020TranscriptPPT
-
Jan 2020TranscriptNotesPPT
-
Dec 2019TranscriptPPT
-
Oct 2019Transcript PPT
-
Jul 2019Transcript PPT
-
Apr 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Oct 2018Transcript PPT
-
Jul 2018TranscriptNotesPPT
-
May 2018TranscriptPPT
-
Apr 2018Transcript PPT
-
Jan 2018TranscriptNotesPPT
-
Nov 2017Transcript PPT
-
Aug 2017Transcript PPT
-
May 2017Transcript PPT
-
Jan 2017TranscriptNotesPPT
-
Oct 2016TranscriptNotesPPT
-
Jul 2016TranscriptNotesPPT
-
Feb 2016TranscriptNotesPPT
-
Oct 2015TranscriptPPT
Business Footprint:[1]
The company caters to diverse end-user industries like Pharmaceuticals, Animal Health, Agrochemicals, Consumer Packaged Goods, Chemicals/Polymers.
It has 400+ active customers with engagements with 13 out of the top 15 global pharma companies. The company holds 400+ patents jointly with clients and has a base of 6000+ scientists.